Ginkgo Bioworks (DNA) Morgan Stanley 22nd Annual Global Healthcare Conference summary

Key accomplishments and business model evolution

• Implemented a 35% reduction in force to streamline costs, especially in the solutions business, focusing on supporting operations with customer fees rather than relying on future royalties and milestones.

• Shifted away from an all-comers approach to a more focused offering in pharma, industrial, and agriculture, leveraging prior work and consolidating around proven capabilities.

• Maintained strong relationships and repeat business with major customers, even during significant organizational changes.

• Preserved a robust cash position of $730 million with no debt, providing flexibility for growth investments.

• Continued to differentiate through proprietary assets like the Foundry and Codebase, now with a more customer-friendly IP approach.

Strategic investments and new offerings

• Investing growth capital in the tools segment, including direct sales of robotics and lab automation equipment, aiming to democratize access to proprietary technology.

• Launched a flexible, modular robotics platform acquired from Zymergen, enabling rapid reconfiguration and protocol updates for customers.

• Monetization strategies for tools include CapEx sales, leasing, and recurring SaaS revenue from software and services.

• Early focus is on establishing marquee customers to drive broader market adoption.

• Introduced Datapoints, a lab data-as-a-service product, providing large, high-quality datasets for AI/ML applications in drug discovery and functional genomics.

Market positioning and industry trends

• Emphasizes a horizontal platform model, aiming to be the high-throughput, high-content data and automation provider across biotech, similar to leading engineering and tools companies.

• Sees growing demand for large, standardized datasets to support AI-driven research, with Datapoints positioned to fill this gap.

• Biosecurity business is transitioning to multi-year, recurring revenue contracts, such as the $94 million CDC traveler genomics program, moving away from episodic COVID-driven revenue.

• Maintains conviction in the horizontal SynBio business model, viewing platform companies as the future of bioengineering.

• Mission remains to make biology easier to engineer, focusing on enabling customers rather than developing proprietary product pipelines.